On March 4, 2022 PharmaMar (MSE:PHM) reported the receipt of payment of $25 million (€22 million) from its U.S. partner, Jazz Pharmaceuticals, after reaching the first commercial milestone, set out in its license agreement in relation to 2021 sales (Press release, PharmaMar, MAR 4, 2022, https://pharmamar.com/en/pharmamar-receives-the-first-commercial-milestone-payment-from-jazz-pharmaceuticals-for-us25-million/ [SID1234609510]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After a successful launch of Zepzelca (lurbinectedin) in the United States by Jazz Pharmaceuticals, lurbinectedin is established as the treatment of choice in second-line SCLC. The sales achieved in 2021 have resulted in the first commercial milestone payment.

Lurbinectedin received accelerated approval for the second-line treatment of SCLC in June 2020 in the United States.

Following the recent $25 million payment, PharmaMar is eligible for additional regulatory milestone payments of up to $153 million and additional commercial milestone payments of up to $528 million related to achieving certain milestones in the U.S. and Canada.